Skip to main content

Table 1 Multivariate analyses of immune cell fraction and patient survival

From: As a prognostic biomarker of clear cell renal cell carcinoma RUFY4 predicts immunotherapy responsiveness in a PDL1-related manner

Variable

HR

95% CI

p-valve

Low

Up

Age (years)

 ≤ 60 (n = 267)

    

 > 60 (n = 270)

1.71

1.231

2.374

0.001

Gender

 Female (n = 186)

    

 Male (n = 351)

   

 > 0.05

Clinical stage

 C1–C3 (n = 452)

    

 C4 (n = 82)

14.832

3.417

64.394

 < 0.001

 CX (n = 3)

    

T stage

 T1 and T2 (n = 348)

    

 T3 and T4 (n = 189)

1.689

1.150

2.482

0.008

M stage

 M0(n = 447)

0.189

0.044

0.811

0.025

 M1 (n = 80)

    

 MX (n = 10)

    

G stage

 G1 and G2 (n = 249)

    

 G3 and G4 (n = 281)

1.797

1.212

2.665

0.004

 GX (n = 7)

    

Tregs

 Low (n = 268)

    

 High (n = 269)

1.494

1.073

2.080

0.018

TFHs

 Low (n = 268)

    

 High (n = 269)

1.589

1.141

2.212

0.006

  1. Multivariate models were adjusted for T, M classification, age, and gender
  2. Hazard ratio, estimated from Cox proportional hazard regression model
  3. Confidence interval of the estimated HR
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us